Ventyx Biosciences Company Insiders
VTYX Stock | USD 1.32 0.01 0.75% |
Ventyx Biosciences employs about 79 people. The company is managed by 11 executives with a total tenure of roughly 185 years, averaging almost 16.0 years of service per executive, having 7.18 employees per reported executive. Break down of Ventyx Biosciences' management performance can provide insight into the company performance.
Insider Sentiment 50
Impartial
Selling | Buying |
Latest Trades
2024-12-27 | John Nuss | Disposed 21119 @ 2.36 | View | ||
2024-12-23 | Sheila Gujrathi | Acquired 130000 @ 2.31 | View | ||
2024-12-19 | John Nuss | Disposed 13161 @ 2.26 | View | ||
2024-11-25 | Raju Mohan | Acquired 261752 @ 2.01 | View | ||
2024-11-22 | Raju Mohan | Acquired 238248 @ 1.83 | View | ||
2024-04-02 | Raju Mohan | Disposed 4312 @ 5.4 | View |
Monitoring Ventyx Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Ventyx |
Ventyx Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.3348) % which means that it has lost $0.3348 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5427) %, meaning that it created substantial loss on money invested by shareholders. Ventyx Biosciences' management efficiency ratios could be used to measure how well Ventyx Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2025. Return On Capital Employed is likely to rise to -0.53 in 2025. At this time, Ventyx Biosciences' Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 38.5 M in 2025, whereas Total Assets are likely to drop slightly above 223.3 M in 2025.Common Stock Shares Outstanding is likely to drop to about 60.6 M in 2025. Net Loss is likely to rise to about (92.7 M) in 2025
Ventyx Biosciences Workforce Comparison
Ventyx Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,654. Ventyx Biosciences claims roughly 79.0 in number of employees contributing just under 2% to equities under Health Care industry.
Ventyx Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ventyx Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ventyx Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ventyx Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Raju Mohan few days ago Disposition of 96778 shares by Raju Mohan of Ventyx Biosciences at 0.2 subject to Rule 16b-3 | ||
Matthew Moore over a week ago Acquisition by Matthew Moore of 320000 shares of Ventyx Biosciences at 4.98 subject to Rule 16b-3 | ||
Gonzales Roy over a week ago Disposition of tradable shares by Gonzales Roy of Ventyx Biosciences subject to Rule 16b-3 | ||
Subramaniam Somu over a week ago Disposition of 1735306 shares by Subramaniam Somu of Ventyx Biosciences subject to Rule 16b-3 | ||
John Nuss over a week ago Disposition of 4531 shares by John Nuss of Ventyx Biosciences subject to Rule 16b-3 | ||
Gujrathi Sheila over two weeks ago Acquisition by Gujrathi Sheila of 33000 shares of Ventyx Biosciences at 3.285 subject to Rule 16b-3 | ||
John Nuss over a month ago Acquisition by John Nuss of 7972 shares of Ventyx Biosciences at 3.54 subject to Rule 16b-3 | ||
Gonzales Roy over two months ago Acquisition by Gonzales Roy of 17500 shares of Ventyx Biosciences at 2.14 subject to Rule 16b-3 |
Ventyx Biosciences Notable Stakeholders
A Ventyx Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ventyx Biosciences often face trade-offs trying to please all of them. Ventyx Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ventyx Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Raju Mohan | CEO, Founder | Profile | |
Matthew Moore | Chief Officer | Profile | |
Snehal Naik | Senior Development | Profile | |
Kye MD | Data Biostatistics | Profile | |
Sheila MD | Executive Chairperson | Profile | |
John Nuss | Chief Officer | Profile | |
Martin MD | Chief Officer | Profile | |
Kathy Ogilvie | Senior Research | Profile | |
Prof MD | Pres Officer | Profile | |
Rosa Ferrao | Senior Affairs | Profile | |
MBA JD | Chief Officer | Profile |
About Ventyx Biosciences Management Performance
The success or failure of an entity such as Ventyx Biosciences often depends on how effective the management is. Ventyx Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ventyx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ventyx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.49) | (0.51) | |
Return On Capital Employed | (0.56) | (0.53) | |
Return On Assets | (0.49) | (0.51) | |
Return On Equity | (0.53) | (0.51) |
Please note, the imprecision that can be found in Ventyx Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ventyx Biosciences. Check Ventyx Biosciences' Beneish M Score to see the likelihood of Ventyx Biosciences' management manipulating its earnings.
Ventyx Biosciences Workforce Analysis
Traditionally, organizations such as Ventyx Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ventyx Biosciences within its industry.Ventyx Biosciences Manpower Efficiency
Return on Ventyx Biosciences Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.7M | |
Net Loss Per Executive | 12.3M | |
Working Capital Per Employee | 2.7M | |
Working Capital Per Executive | 19.7M |
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.